Literature DB >> 8663948

HSV-tk gene therapy in head and neck squamous cell carcinoma. Enhancement by the local and distant bystander effect.

K M Wilson1, P J Stambrook, W L Bi, Z P Pavelic, L Pavelic, J L Gluckman.   

Abstract

OBJECTIVES: To determine whether the bystander effect demonstrated in vitro for ganciclovir-mediated killing of a herpes simplex virus thymidine kinase (HSV-tk) gene-infected human squamous cell carcinoma is operative in vivo in a nude mouse model.
DESIGN: Prospective study in a murine model. INTERVENTION: Human head and neck squamous cell carcinoma tumors were grown as xenografts on the flanks of 20 nude mice. The tumors in the left flank were then infected with the HSV-tk gene. Then, after 48 hours, the animals were treated with intraperitoneal ganciclovir twice daily. Assessment of the tumors on both flanks was performed over a 31-day period. MAIN OUTCOME MEASURES: Resolution of tumors infected with HSV-tk gene in animals treated with ganciclovir; resolution of tumors uninfected with HSV-tk gene on the contralateral flank in animals treated with ganciclovir.
RESULTS: Following HSV-tk gene therapy in nude mice, complete resolution of HSV-tk-gene-infected human head and neck squamous cell carcinoma tumors was observed following ganciclovir treatment. Uninfected tumors were also noted to regress, but not completely resolve, in response to intraperitoneal ganciclovir (distant bystander effect).
CONCLUSIONS: This study confirms that the local and distant bystander effects exist in this murine model, enhancing the possibility of its role for treatment of human squamous cell carcinoma of the head and neck.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8663948     DOI: 10.1001/archotol.1996.01890190042011

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  6 in total

1.  Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

Authors:  A Chahlavi; T Todo; R L Martuza; S D Rabkin
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

Review 2.  Gene-directed enzyme prodrug therapy.

Authors:  Jin Zhang; Vijay Kale; Mingnan Chen
Journal:  AAPS J       Date:  2014-10-23       Impact factor: 4.009

Review 3.  Gene therapy and targeted toxins for glioma.

Authors:  Maria G Castro; Marianela Candolfi; Kurt Kroeger; Gwendalyn D King; James F Curtin; Kader Yagiz; Yohei Mineharu; Hikmat Assi; Mia Wibowo; A K M Ghulam Muhammad; David Foulad; Mariana Puntel; Pedro R Lowenstein
Journal:  Curr Gene Ther       Date:  2011-06       Impact factor: 4.391

Review 4.  Gene therapy and targeted toxins for glioma.

Authors:  Gwendalyn D King; James F Curtin; Marianela Candolfi; Kurt Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

5.  Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats.

Authors:  V Pierrefite-Carle; P Baqué; A Gavelli; N Brossette; D Benchimol; A Bourgeon; M C Saint Paul; P Staccini; B Rossi
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

6.  Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.

Authors:  Gwendalyn D King; A K M Ghulam Muhammad; James F Curtin; Carlos Barcia; Mariana Puntel; Chunyan Liu; Sarah B Honig; Marianela Candolfi; Sonali Mondkar; Pedro R Lowenstein; Maria G Castro
Journal:  Neuro Oncol       Date:  2007-12-13       Impact factor: 12.300

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.